RxDoctor Payments Data

Zoltan Toth, MD

Clinical Cardiac Electrophysiology · Austin, TXNPI 1093719882

Payments from drug & device makers

$20,829in general payments, 2019–2025

Across 697 payments — averaging $29.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Boston Scientific$7K
  • Abbott$4K
  • Biosense Webster, Inc.$811
  • E.r. Squibb & Sons, L.L.C.$802
  • Medical Device Business Services, Inc.$313
  • plus $672 from 11 others

What the payments were for

  • Consulting fees$2501%
  • Travel & lodging$6,07329%
  • Food & beverage$14,50670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,829 in reported general payments places this provider in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$336,473
Medicare patients
593
Services billed
4,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$245,444
MultaqDronedarone Hcl65$74,966
XareltoRivaroxaban44$45,886
Dofetilide49$6,896
Flecainide Acetate135$3,791
Metoprolol Succinate158$2,778
ClopidogrelClopidogrel Bisulfate147$1,780
Mexiletine Hcl15$1,716
Amiodarone Hcl64$1,176
Sucralfate39$600
Digoxin29$541
Diltiazem 24hr Er (Cd)Diltiazem Hcl20$460
Metoprolol Tartrate63$446
SotalolSotalol Hcl17$369
Carvedilol79$358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$245,444257 claims
Sanofi-aventis U.S. LLCMultaq$94$74,96665 claims
Johnson & JohnsonXarelto$148$45,88644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →